他泽司他治疗上皮样肉瘤的效果怎么样？

Epithelioid sarcoma (ES) is a rare type of soft tissue sarcoma (STS). It is common in young people and has a small number of patients. It accounts for ≤1% of STS patients. Cancer cells in ES patients can spread rapidly in various organs of the human body in a short period of time, and the 1-year survival rate is less than 50%. Patients with this disease have no obvious symptoms in the early stage of the disease, and the disease progresses slowly, so they are often misdiagnosed or missed during the clinical diagnosis process. Among them, >70% of patients are already in the intermediate and advanced stages of cancer when first diagnosed, and the proportion of patients who have received at least one treatment method is ≥50%, and most patients have even developed obvious drug resistance or no available drugs. Although ES is clinically rare and has a high fatality rate, the clinical research data shows that this drug may provide new treatment methods and directions for these patients.

Tazerestat is an EZH2 enzyme inhibitor developed by Epizyme Company under the trade name Tazverik. On January 23, 2020, the U.S. FDA approved tazerestat for the treatment of epithelioid sarcoma that is not suitable for surgical resection, metastasis, or locally advanced epithelioid sarcoma in patients 16 years of age and older. So, how effective is tazerestat in the treatment of epithelioid sarcoma?

The approval of tazetostat by the US FDA was based on the results of a multi-center, open-label, single-arm phase II clinical study (EZH-202 study, NCTO2601950). A total of 62 subjects with epithelioid sarcoma were recruited into the study, with a median age of 34 years. The study results showed that the ORR of tazerestat among all subjects was 15%, of which 1.6% achieved complete response, 13% achieved partial response, and 67% of the subjects responded for more than 6 months. The study reached the primary clinical endpoint.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.